Diagnostic Pathology (Sep 2010)

Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer

  • Huo Shufen,
  • Bu Lina,
  • Nan Yandong,
  • Lin Xiuli,
  • Yang Shuanying,
  • Du Jie,
  • Shang Wenli

DOI
https://doi.org/10.1186/1746-1596-5-60
Journal volume & issue
Vol. 5, no. 1
p. 60

Abstract

Read online

Abstract Background The purpose of this study is to discover potential biomarkers in serum for the detection of small cell lung cancer (SCLC). Methods 74 serum samples including 30 from SCLC patients and 44 from healthy controls were analyzed using ClinProt system combined with matrix-assisted laser desorption/ionization time-of-flight masss spectrometry (MALDI-TOF-MS). ClinProt software and genetic algorithm analysis selected a panel of serum markers that most efficiently predicted which patients had SCLC. Results The diagnostic pattern combined with 5 potential biomarkers could differentiate SCLC patients from healthy persons, with a sensitivity of 90%, specificity of 97.73%. Remarkably, 88.89% of stage I/II patients were accurately assigned to SCLC. Conclusions Anchorchip-time-of-flight spectrometry technology will provide a highly accurate approach for discovering new biomarkers for the detection of SCLC.